Xeris Biopharma Holdings (XERS) Amortization - Intangibles (2021 - 2026)

Xeris Biopharma Holdings' Amortization - Intangibles history runs 6 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Amortization - Intangibles changed 0.0% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 million (changed 0.01% YoY) and the FY2025 annual result came in at $10.8 million, changed 0.0% from the prior year.
• Amortization - Intangibles was $2.7 million for Q1 2026 at Xeris Biopharma Holdings, roughly flat from $2.7 million in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $2.7 million in Q1 2022 and bottomed at $2.7 million in Q2 2022.
• A 5-year average of $2.7 million and a median of $2.7 million in 2022 frame the typical range for Amortization - Intangibles.
• Annual changes were most pronounced in 2022 — Amortization - Intangibles jumped 392.91% — and 2025, when it fell 0.04%.
• Xeris Biopharma Holdings' Amortization - Intangibles stood at $2.7 million in 2022, then changed by 0.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then changed by 0.0% to $2.7 million in 2025, then dropped by 0.04% to $2.7 million in 2026.
• Business Quant data shows XERS's Amortization - Intangibles at $2.7 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.